Probability of Major Depression Classification Based on the SCID, CIDI, and MINI Diagnostic Interviews : A Synthesis of Three Individual Participant Data Meta-Analyses by Wu, Yin et al.
Innovations
Psychother Psychosom
Probability of Major Depression Classification 
Based on the SCID, CIDI, and MINI Diagnostic 
Interviews: A Synthesis of Three Individual 
Participant Data Meta-Analyses
Yin Wu a, b    Brooke Levis a, c, d    John P.A. Ioannidis e    Andrea Benedetti c, f, g    
Brett D. Thombs a, b, c, f, g, h, i     DEPRESsion Screening Data (DEPRESSD) 
Collaboration    
a
 Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada; b Department of 
Psychiatry, McGill University, Montreal, QC, Canada; c Department of Epidemiology, Biostatistics, and Occupational 
Health, McGill University, Montreal, QC, Canada; d Centre for Prognosis Research, School of Primary, Community and 
Social Care, Keele University, Keele, UK; e Departments of Medicine, Health Research and Policy, Biomedical Data 
Science, and Statistics, Stanford University, Stanford, CA, USA; f Respiratory Epidemiology and Clinical Research Unit, 
McGill University Health Centre, Montreal, QC, Canada; g Department of Medicine, McGill University,  
Montreal, QC, Canada; h Department of Psychology, McGill University, Montreal, QC, Canada; i Department of 
Educational and Counselling Psychology, McGill University, Montreal, QC, Canada
Received: March 17, 2020
Accepted: June 5, 2020
Published online: August 19, 2020
Brett D. Thombs, PhD
Jewish General Hospital
4333 Cote Ste Catherine Road
Montreal, QC H3T 1E4 (Canada)
brett.thombs @ mcgill.ca
Andrea Benedetti, PhD
Centre for Outcomes Research and Evaluation
Research Institute of the McGill University Health Centre
5252 Boulevard de Maisonneuve, Montréal, QC H4A 3S5 (Canada)
andrea.benedetti @ mcgill.ca




Depressive disorders · Diagnostic interviews ·  
Individual participant data meta-analysis · Major 
depression · Classification
Abstract
Introduction: Three previous individual participant data 
meta-analyses (IPDMAs) reported that, compared to the 
Structured Clinical Interview for the DSM (SCID), alternative 
reference standards, primarily the Composite International 
Diagnostic Interview (CIDI) and the Mini International Neu-
ropsychiatric Interview (MINI), tended to misclassify major 
depression status, when controlling for depression symp-
tom severity. However, there was an important lack of pre-
cision in the results. Objective: To compare the odds of the 
major depression classification based on the SCID, CIDI, and 
MINI. Methods: We included and standardized data from 3 
IPDMA databases. For each IPDMA, separately, we fitted bi-
nomial generalized linear mixed models to compare the ad-
justed odds ratios (aORs) of major depression classification, 
controlling for symptom severity and characteristics of par-
ticipants, and the interaction between interview and symp-
tom severity. Next, we synthesized results using a DerSimo-
nian-Laird random-effects meta-analysis. Results: In total, 
69,405 participants (7,574 [11%] with major depression) 
from 212 studies were included. Controlling for symptom 
severity and participant characteristics, the MINI (74 stud-
ies; 25,749 participants) classified major depression more 
often than the SCID (108 studies; 21,953 participants; aOR 
1.46; 95% confidence interval [CI] 1.11–1.92]). Classification 
odds for the CIDI (30 studies; 21,703 participants) and the 
SCID did not differ overall (aOR 1.19; 95% CI 0.79–1.75); 
however, as screening scores increased, the aOR increased 
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less for the CIDI than the SCID (interaction aOR 0.64; 95% CI 
0.52–0.80). Conclusions: Compared to the SCID, the MINI 
classified major depression more often. The odds of the de-
pression classification with the CIDI increased less as symp-
tom levels increased. Interpretation of research that uses 
diagnostic interviews to classify depression should consid-
er the interview characteristics. © 2020 S. Karger AG, Basel
Introduction
In mental health research, diagnostic interviews are 
used to classify disorders in a manner consistent with 
standard classification systems and replicable across stud-
ies [1–4]. There are important differences, however, in the 
designs of commonly used interviews. Semi-structured 
interviews are designed for administration by trained pro-
fessionals with diagnostic experience; evaluators can in-
terject queries and use their clinical judgment to deter-
mine whether symptoms are present and significant [1–
3]. The Structured Clinical Interview for the DSM (SCID) 
[4] is the most commonly used semi-structured interview 
in depression research [5–7]. Fully structured interviews, 
in contrast, are designed for lay-interviewer administra-
tion to reduce the cost of clinician-administered inter-
views. They are completely scripted, and evaluators can-
not provide additional explanations or rephrase ques-
tions; minimal judgment is involved. They are intended to 
maximize reliability but may reduce validity [8]. The 
Composite International Diagnostic Interview (CIDI) [8] 
is the most commonly used fully structured interview in 
depression research [5–7]. The Mini International Neuro-
psychiatric Interview (MINI) [9, 10], also common in de-
pression research, is a very brief, fully structured inter-
view, originally described by its developers as a screening 
interview and intended to be over-inclusive [10]. 
Despite their differences, semi-structured interviews, 
fully structured interviews of conventional length, and 
abbreviated alternatives such as the MINI are usually 
treated as equivalent. For instance, meta-analyses of the 
accuracy of depression screening tools typically pool the 
primary study results without considering the reference 
standards [11–17]. Until recently, however, only several 
small studies, each with ≤61 cases of depression, com-
pared classifications made by different diagnostic inter-
views [2, 18–23]. Recently, 3 individual participant data 
meta-analyses (IPDMA) compared the odds of major de-
pression classification between different diagnostic inter-
views, controlling for symptom severity scores and the 
characteristics of participants [5–7]. These included an 
IPDMA with 17,158 participants from 57 primary studies 
that used the Patient Health Questionnaire-9 (PHQ-9) to 
control for depression symptom severity [5], 12,759 
women in pregnancy or postpartum from 46 studies that 
used the Edinburgh Postnatal Depression Scale (EPDS) 
[6], and 15,856 participants from 73 studies that used the 
depression subscale of the Hospital Anxiety and Depres-
sion Scale (HADS-D) [7]. The results suggested that, 
compared to semi-structured interviews (e.g., the SCID) 
[4], the CIDI may classify more people with relatively 
low-level symptoms as depressed but fewer people with 
higher symptom levels. The MINI appeared to classify 
major depression in more people across the symptom 
spectrum. There was important imprecision in results, 
however, including wide confidence intervals (CIs) 
around estimates.
Our objective was to synthesize results from 3 separate 
IPDMA datasets to compare the most commonly used 
diagnostic interviews for major depression, i.e., the SCID, 
CIDI, and MINI, in order to determine (1) if the adjusted 
odds ratios (aORs) for major depression classification us-
ing the CIDI and MINI differ from those of the SCID, 
when controlling for depression symptom severity and 
participant characteristics, and (2) if there is an interac-
tion between the interview and depressive symptom level 
that would suggest that differences in classification odds 
are associated with symptom levels. 
Materials and Methods
We conducted a 2-stage evidence synthesis. We first conducted 
IPDMA of the PHQ-9, EPDS, and HADS datasets, separately, by 
fitting models with and without interaction terms for depressive 
symptom severity in each dataset, separately. Second, we pooled 
estimates from the results of the 3 IPDMAs. 
Inclusion Criteria for the Included Datasets
For the PHQ-9, EPDS, and HADS-D IPDMAs, datasets from 
articles in any language were eligible for inclusion if (1) they in-
cluded diagnostic classification for current Major Depressive Dis-
order or Major Depressive Episode using Diagnostic and Statistical 
Manual of Mental Disorders (DSM) [24–27] or International Clas-
sification of Diseases (ICD) [28] criteria based on a validated, 
semi-structured or fully structured interview; (2) they included 
PHQ-9, EPDS, or HADS-D scores; (3) the diagnostic interview 
and depression screening test were administered within 2 weeks of 
each other; and (4) participants were ≥18 years of age, not recruit-
ed from youth or college settings, and not recruited from psychi-
atric settings or because they had been identified as having symp-
toms of depression [29–31].
For the EPDS, participants were women who were pregnant or 
























   
   
   
   
   
   

























where not all participants were eligible were included if primary 
data allowed the selection of eligible participants [29–31]. Over 
90% of all the included studies in the IPDMA databases used the 
SCID, CIDI, or MINI diagnostic interview. Therefore, as we had 
for the published IPDMAs of the EDPS [6] and HADS-D [7], we 
restricted our analyses to studies that used the SCID, CIDI, or 
MINI. 
Search Strategy, Study Selection, and Acquisition and 
Extraction of Data
More details on the search and selection processes as well as 
data contribution, extraction, and synthesis can be found in online 
supplementary Method 1 (for all online suppl. material, see www.
karger.com/doi/10.1159/000509283). For information on how the 
IPDMA datasets and our analyses deviated from our previous pub-
lished IPDMAs on diagnostic interview performance using the 
PHQ-9 [5], EPDS [6], and HADS-D [7] IPDMA databases, please 
see online supplementary Methods 2 and 3, and Figure 1.
Statistical Analysis
IPDMA of PHQ-9, EPDS, and HADS-D Datasets
We initially standardized symptom severity scores in each da-
taset. To do this, for each measure, we converted the raw screen-
ing-tool scores to standardized scores by Z-transformation (sub-
tracting the mean and dividing by the SD of the raw scores). We 
then analyzed the PHQ-9, EPDS, and HADS datasets separately. 
In each dataset, we fitted binomial generalized linear mixed mod-
els with a logit link function to compare the aOR of major depres-
sion classification for the CIDI versus the SCID, the MINI versus 
the SCID, and, as a supplementary analysis, the MINI versus the 
CIDI, controlling for depressive symptom levels and other par-
ticipant characteristics.
We adjusted for different covariates in the models for each da-
taset, based on relevant measures. For the PHQ-9 and HADS-D 
datasets, as in the previously published IPDMAs [5, 7], we con-
trolled for depressive symptom severity (continuous standardized 
scores), age, sex, country Human Development Index (very high, 
high, or low-to-medium) [32], and patient care setting (PHQ-9: 
primary care, outpatient specialty care, inpatient specialty care, or 
non-medical care [33]; HADS-D: outpatient care, inpatient care, 
non-medical care, or mixed inpatient and outpatient [7]). For the 
EPDS, we did not control for sex or patient care settings but for 
pregnancy versus postpartum status [6]. To account for the cor-
relation between subjects within primary studies in each dataset, a 
random intercept was fitted. Fixed slopes were estimated for all 
covariates in each model. We also fitted additional models in each 
dataset, where we added an interaction term between interview 
and symptom severity (continuous PHQ-9, EPDS, and HADS-D 
standardized scores), to evaluate whether any differences in aORs 
of major depression classification were associated with depression 
symptom severity. 
Synthesis of IPDMA Results
To synthesize results from the 3 IPDMAs, we pooled estimates 
of the aOR for each comparison (CIDI vs. SCID, MINI vs. SCID, 
and MINI vs. CIDI) and the aOR for the interaction of interview 
and depression symptom severity in each comparison, along with 
its 95% CI. We used a DerSimonian-Laird random effects meta-
analysis to pool the aORs [34]. Heterogeneity was examined using 
the I2 statistic based on log aORs [35]. Because some studies were 
included in both the PHQ-9 and HADS-D IPDMAs, as a sensitiv-











SCID PHQ-9 44 9,186 1,384 (15)
EPDS 28 7,279 1,017 (14)
HADS-D 36 5,488 607 (11)
Total 108 21,953 3,008 (14)
CIDI PHQ-9 17 15,732 1,065 (7)
EPDS 3 2,948 194 (7)
HADS-D 10 3,023 269 (9)
Total 30 21,703 1,528 (7)
MINI PHQ-9 32 15,872 1,630 (10)
EPDS 15 2,532 342 (14)
HADS-D 27 7,345 1,066 (15)
Total 74 25,749 3,038 (12)
All interviews 212 69,405 7,574 (11)
CIDI, Composite International Diagnostic Interview; EPDS, Edinburgh Postnatal Depression Scale; HADS-D, 
Depression subscale of Hospital Anxiety and Depression Scale; MINI, Mini International Neuropsychiatric 
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ity analysis, we re-analyzed the results after removing these stud-
ies.
All analyses were conducted in R (R v3.5.1 and Studio v1.1.463) 
[36, 37] using the glmer function within the lme4 package [38] and 
the rma function within the metafor package [39]. 
Results
In total, 69,405 participants (7,574 [11%] with major 
depression) were included in the 3 individual IPDMAs 
(Table 1). Of the 212 included primary studies, the SCID 
was used in 108 studies (21,953 participants, 14% with 
major depression), the CIDI in 30 studies (21,703 par-
ticipants, 7% with major depression), and the MINI in 74 
studies (25,749 participants, 12% with major depression). 
The mean (SD) of raw screening-tool scores, prior to 
standardization, was 4.99 (5.26) for the PHQ-9, 6.98 
(5.58) for the EPDS, and 5.16 (4.07) for the HADS-D. 
Characteristics of individual primary studies are avail- 
able in online supplementary Table 1 and the details of 
the PHQ-9 update in online supplementary Method 1. 
Thirteen studies were included in both the PHQ-9 and 
HADS-D datasets, involving 2,383 (6%) participants in 
the PHQ-9 IPDMA and 2,349 (15%) in the HADS-D 
IPDMA. There was no overlap between the EPDS and the 
PHQ-9 or HADS-D IPDMAs. 
Estimates of aORs of major depression classification by 
diagnostic interview, controlling for depressive symptom 
severity and other participant characteristics, individually 
and pooled, are reported in Table 2. The overall odds of 
major depression classification did not differ for the CIDI 
and SCID (aOR 1.19; 95% CI 0.79–1.75) in the full model 
that included the interaction term, but there was a signif-
icant interaction between the CIDI and depressive symp-
tom severity; as screening-tool scores increased, the odds 
of major depression classification increased less for the 
CIDI than for the SCID (interaction aOR 0.64; 95% CI 
0.52–0.80). As shown in Figure 1, participants with lower 
depressive symptom severity were more likely to be clas-
sified with major depression by the CIDI than by the 
SCID, but the opposite was true with greater symptom 
severity. Compared to the SCID, the MINI classified ma-
jor depression more often (aOR 1.45; 95% CI 1.08–1.93), 
when controlling for depressive symptom severity and 
participant characteristics. There was no apparent inter-
action between symptom levels and odds of classification 
(interaction aOR 0.95; 95% CI 0.78–1.15) (Fig. 2). 
Trends of the probability of major depression classifi-
cation by reference standards for individual IPDMAs are 
presented in online supplementary Fig. 2–4. There was 
minimal between-IPDMA heterogeneity of overall aORs 























Fig. 1. Comparison of major depression 
classification odds of the Composite Inter-
national Diagnostic Interview (CIDI) vs. 
the Structured Clinical Interview for DSM 
(SCID). Adjusted odds ratio (aOR) of the 
major depression classification for the 
CIDI compared to the SCID in primary 
studies based on the PHQ-9, EPDS, and 
HADS-D and pooled estimates at stan-
dardized scores. The standardized scores of 
–1, 0, 1, 2, and 3 are approximately equal to 
scores of 0, 5, 10, 16, and 21 on the PHQ-9 
(SD 5.26); 1, 7, 13, 18, and 24 on the EPDS 
(SD 5.58); and 1, 5, 9, 13, and 17 on the 
HADS-D (SD 4.07). We present standard-
ized scores from –1 to 3, because raw scores 
corresponding to standardized scores be-
low –1 or above 3 would be negative or be-
yond the maximum scores of the included 
screening tools. EPDS, Edinburgh Postna-
tal Depression Scale; HADS-D, Depression 
subscale of Hospital Anxiety and Depres-
sion Scale; META, Pooled estimates from 
the synthesis meta-analysis; PHQ-9, Pa-






































   
   
   
   
   
   

























MINI versus the SCID in models without the interaction 
term (I2 = 11% and 0%, respectively) and including the 
interaction term (I2 = 0% and 0%, respectively). However, 
there was substantial between-IPDMA heterogeneity of 
interaction aORs for both comparisons (I2 = 82% and 
82%; Table 2).
In the comparison of the MINI versus the CIDI, the 
MINI was more likely to classify participants as having 
major depression (aOR 2.05; 95% CI 1.36–2.10), control-
ling for depressive symptom levels and other participant 
characteristics. As screening-tool scores increased, the 
odds of major depression classification increased more 
for the MINI than for the CIDI (interaction aOR 1.48; 
95% CI 1.36–1.60). Heterogeneity was low for aORs with/
without the interaction term and interaction aORs (I2 = 
0%, 0%, and 0%, respectively). 
In the individual IPDMAs, some results from the EPDS 
dataset appeared to diverge from those generated in the 
PHQ-9 and HADS-D datasets. However, the number of 
studies and cases included in the EPDS dataset for the 
CIDI and MINI were smaller than any other combination 
of screening tool and diagnostic interview (Table 1).
As a sensitivity analysis, we removed the 13 datasets 
included in both the PHQ-9 and HADS-D IPDMAs and 
re-ran all analyses. This produced similar results (online 
suppl. Table 2). 
Discussion
There were 2 main findings. First, the overall odds of 
major depression classification did not differ between the 
fully structured CIDI and the semi-structured SCID. 
However, adjusting for depressive symptom levels and 
participant characteristics, the odds of major depression 
classification with the CIDI increased significantly less 
than those for the SCID did, as levels of depressive symp-
toms increased. This suggests that, compared to the SCID, 
the CIDI is relatively more likely to classify individuals 
with sub-threshold or mild depressive symptoms and rel-
atively less likely to classify people with more severe 
symptoms. Second, participants evaluated with the MINI 
were significantly more likely to be classified as having 
major depression than those assessed with the SCID, in-
dependent of symptom severity. Between-study hetero-
geneity was low for models without the interaction term 
but higher for models with interaction terms. The EPDS 
IPDMA estimates appeared to diverge somewhat from 
the PHQ-9 and HADS-D IPDMAs. This may have been 
related to the small numbers of studies and major depres-
sion cases for the CIDI and MINI among studies that used 
the EPDS. 
Our findings appear to be consistent with character-























Fig. 2. Comparison of major depression 
classification odds of the Mini Internation-
al Neuropsychiatric Interview (MINI) vs. 
the SCID considering the interaction be-
tween depressive symptom severity and the 
MINI. aOR of major depression classifica-
tion for the MINI compared to the SCID 
for primary studies based on the PHQ-9, 
EPDS, and HADS-D and pooled estimates 
at standardized scores. The standardized 
scores of –1, 0, 1, 2, and 3 are approximate-
ly equal to scores of 0, 5, 10, 16, and 21 on 
the PHQ-9 (SD 5.26); 1, 7, 13, 18, and 24 on 
the EPDS (SD 5.58); and 1, 5, 9, 13, and 17 
on the HADS-D (SD 4.07). We present 
standardized scores from –1 to 3, because 
raw scores corresponding to standardized 
scores below –1 or above 3 would be nega-
tive or beyond the maximum scores of the 
included screening tools. EPDS, Edinburgh 
Postnatal Depression Scale; HADS-D, De-
pression subscale of Hospital Anxiety and 
Depression Scale; META, pooled estimates 
from the synthesis meta-analysis; PHQ-9, 
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MINI was designed as a screening interview and de-
scribed by its developers as over-inclusive in classifying 
psychiatric disorders [10]. For the CIDI, the lack of sen-
sitivity to different levels of depressive symptoms sever-
ity may be because it assesses symptoms in the last 12 
months and over the lifetime, then probing to deter-
mine if the symptoms are currently present by means of 
a single question. In contrast, the SCID and the MINI 
specifically assess symptoms in the past 2 weeks. In ad-
dition, the CIDI is much more complicated than the 
MINI or the SCID. It includes complex branches and is 
scored using algorithms subject to calibration, which 
may influence how well diagnoses map onto the DSM 
criteria. This could lead to error at all symptom levels, 
which would result in more people being classified at 
lower symptom severity levels and fewer at higher lev-
els.
The results were generally consistent with limited evi-
dence from small studies that previously directly com-
pared depression classification by administering semi- 
and fully structured diagnostic interviews to the same 
participants. In 2 studies that examined general popula-
tion samples with low prevalence, the fully structured in-
terviews classified major depression substantially more 
frequently than the semi-structured interviews did [2, 
20]. On the other hand, in a study of participants under-
going inpatient alcohol treatment, where the symptom 
severity would be expected to be higher, the depression 









aOR (95% CI) aOR (95% CI) aOR for interaction 
(95% CI)
CIDI vs. SCID PHQ-9 0.81 (0.50–1.33) 1.15 (0.69–1.92) 0.73 (0.66–0.81)
EPDSc 0.34 (0.09–1.34) 0.66 (0.15–2.82) 0.50 (0.41–0.61)
HADS-Dc 1.09 (0.56–2.13) 1.40 (0.72–2.74) 0.71 (0.59–0.84)
Pooled 0.83 (0.54–1.27) 1.19 (0.79–1.75) 0.64 (0.52–0.80)
I2, % 11 0 82
MINI vs. SCID PHQ-9 1.62 (1.05–2.50) 1.43 (0.91–2.25) 1.11 (1.00–1.24)
EPDSc 0.91 (0.43–1.94) 1.15 (0.52–2.50) 0.76 (0.62–0.93)
HADS-Dc 1.52 (1.01–2.30) 1.57 (1.03–2.40) 0.96 (0.84–1.09)
Pooled 1.46 (1.11–1.92) 1.45 (1.08–1.93) 0.95 (0.78–1.15)
I2, % 0 0 82
MINI vs. CIDI PHQ-9d 2.00 (1.13–3.54) 1.34 (0.75–2.38) 1.52 (1.37–1.68)
EPDSc 3.72 (1.21–11.43) 2.83 (0.85–9.33) 1.49 (1.18–1.88)
HADS-Dc 1.70 (0.84–3.43) 1.40 (0.71–2.76) 1.34 (1.13–1.58)
Pooled 2.05 (1.36–2.10) 1.49 (0.99–2.25) 1.48 (1.36–1.60)
I2, % 0 0 0
aOR, adjusted odds ratio; CI, confidence interval; CIDI, Composite International Diagnostic Interview; EPDS, 
Edinburgh Postnatal Depression Scale; HADS-D, Depression subscale of Hospital Anxiety and Depression Scale; 
MINI, Mini International Neuropsychiatric Interview; PHQ-9, Patient Health Questionnaire-9; SCID, Structured 
Clinical Interview for DSM.
a No interaction; adjusted for depression symptom severity (standardized PHQ-9, EPDS, or HADS-D scores), 
age, and country human development index for all 3 IPDMAs, sex and patient care setting for the PHQ-9 and 
HADS-D IPDMAs, and pregnancy status (pregnant vs. postpartum) for the EPDS.
b Including an interaction between diagnostic interview and PHQ-9, EPDS, or HADS-D scores; adjusted for 
depression symptom severity (standardized PHQ-9, EPDS, or HADS-D scores), age, and country Human 
Development Index for all 3 IPDMAs, sex and patient care setting for the PHQ-9 and HADS-D IPDMAs, and 
pregnancy status (pregnant vs. postpartum) for the EPDS.
c  Results are slightly different from previously published results [6, 7] in terms of adjusted ORs for the 
interactions due to using standardized rather than raw scores in our analyses.
d Only the 2 models of MINI vs. CIDI converged with the default optimizer in glmer, so we used bobyqa 
























   
   
   
   
   
   

























classification likelihood was similar for the semi-struc-
tured and fully structured interviews [22]. 
Our findings have important implications for research, 
including clinical trials, prognostic and risk-factor stud-
ies, diagnostic accuracy studies, and prevalence studies. 
Concerns have been raised about the degree to which an-
tidepressant trials are generalizable to real-world clinical 
practice [40]. Based on our findings, the method used to 
classify depression status is clearly also an important con-
sideration. If used to determine trial eligibility, the CIDI 
may not identify some participants who would be eligible 
according to the SCID, but then the CIDI and MINI may 
both include some participants who would not be eligible 
according to the SCID. This could reduce the ability to 
detect treatment effects and further limit applicability to 
participants in practice who meet the diagnostic criteria. 
Differences in classifying participants could similarly re-
duce the ability to identify potential associations between 
risk factors and depression. In studies of diagnostic test 
accuracy, the accuracy of the depression screening tool 
has been shown to differ across reference standards [33, 
41, 42]. In studies of major depression prevalence, the 
MINI tends to overestimate compared to the SCID where-
as with the CIDI, relative prevalence will depend on the 
underlying distribution of depressive symptoms. 
Our findings, which are contrary to the common belief 
that different reference standards can be treated equiva-
lently in mental health research, provide evidence that 
different approaches are needed [43]. Ideally, researchers 
should use semi-structured interviews, such as the SCID, 
which are designed to replicate diagnostic procedures as 
closely as possible, to establish diagnostic status. How-
ever, this is not always feasible due to the resources re-
quired, including highly trained staff. Future studies are 
needed to develop models to calibrate weights of major 
depression classification, based on different reference 
standards that could facilitate the synthesis of results of 
different diagnostic interviews. Meanwhile, in selecting a 
diagnostic interview for use in research, investigators 
should consider the advantages and disadvantages of the 
different types of interviews, including the performance 
characteristics and the resources required. In published 
studies, authors should comment on the potential impli-
cations of the type of diagnostic interview that has been 
used. Users of research, including clinicians, should be 
aware that results in studies that use the CIDI or MINI 
may differ from those found when using semi-structured 
interviews which are designed to replicate diagnostic pro-
cedures as closely as possible. It is also important to un-
derline that, from a clinimetric perspective [44–46], the 
assessment of diagnostic status alone is not sufficient and 
rating tools and self-report questionnaires are also need-
ed to characterize symptom severity and the specific na-
ture of the symptoms experienced.
A strength of this study was the inclusion of 69,405 
participants with 7,574 (11%) major depression cases 
from 212 studies. This allowed us to overcome the limita-
tions of previous IPDMAs and generate more precise es-
timates. A second strength was that data within each in-
cluded dataset was standardized in terms of the defini-
tions of major depression classification, the eligibility 
criteria, and the variables.
A limitation to consider is that for the IPDMAs we in-
cluded, we could not obtain primary data for 28/117 
PHQ-9 studies (24% of eligible studies and 17% of eligible 
participants), 19/64 EPDS studies (30% of eligible studies 
and 30% of eligible participants), and 47/116 HADS-D 
studies (41% of eligible studies and 29% of eligible par-
ticipants). The second is that we used standardized scores 
instead of raw depression symptom scores, which re-
quired making the assumption that a SD change in scores 
was equivalent across the different screening tools. Third, 
because only 3 estimates were pooled, our ability to esti-
mate heterogeneity and explore possible causes was lim-
ited. Fourth, some studies were included in the IPDMA 
of both the PHQ-9 and the HADS-D, although a sensitiv-
ity analysis showed that the results were similar when 
these studies were removed. Fifth, we examined the SCID, 
CIDI, and MINI because we did not have access to enough 
studies to include other diagnostic interviews. It is un-
clear to what degree our findings would generalize to oth-
er types of diagnostic interviews. Finally, our study did 
not include a head-to-head comparison of interviews 
from a randomized controlled trial or by administering 
different interviews to all participants. It is unlikely, how-
ever, that such a study would be feasible with a large 
enough sample to draw conclusions with confidence. Our 
study design, despite its limitations, overcame this bar-
rier.
To conclude, the semi-structured SCID was designed 
to replicate diagnostic standards and procedures as close-
ly as possible. By synthesizing results from 3 large 
IPDMAs, we found that the most commonly used fully 
structured diagnostic interviews to classify major depres-
sion, the CIDI and MINI, did not perform equivalently to 
the SCID. The CIDI is not as responsive as the SCID to 
different levels of reported depressive symptoms, and the 
MINI identifies more cases across the spectrum of de-
pressive symptom levels. Researchers should carefully 
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diagnostic interviews, and findings from studies based on 
the CIDI or the MINI should be interpreted by taking into 
consideration how their performance deviates from that 
of the SCID.
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